IMMUNE CHECKPOINT INHIBITORS MARKET
Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patientsu2019 immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.
151 views • 11 slides
![[PDF READ ONLINE] Hope . . . From the Heart of Horses: How Horses Teach Us About Presence,](https://cdn7.slideserve.com/12390791/slide1-dt.jpg)
![[READ DOWNLOAD] The Horses Return: The Horses Know Book 3 (The Horses Know Trilogy)](https://cdn7.slideserve.com/12397921/slide1-dt.jpg)